• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Topics » BioWorld Science

BioWorld Science
BioWorld Science RSS Feed RSS

Cardiovascular

Glucagon receptor antagonism’s beneficial effect on heart failure described

Aug. 27, 2024
Heart failure with preserved ejection fraction (HFpEF) is associated with hypertension and metabolic disorders and remains one of the main challenges for cardiovascular risk management. Researchers from the University of Cincinnati, Duke University School of Medicine, Remd Biotherapeutics Inc. and collaborators described the use of targeted inhibition of glucagon signaling as a potential strategy to rescue the pathological features of HFpEF.
Read More
Antibodies
Cancer

Novel anti-LIF antibody manifests relevant antitumor effect

Aug. 27, 2024
Leukemia inhibitory factor (LIF) is an IL-6 type cytokine involved in the inflammatory response, stem cell self-renewal and tumor progression, that binds to LIFR and gp130 on the cell surface. LIF is overexpressed in several types of cancer such as pancreatic, breast or prostate cancer and thus is considered a therapeutic target for the treatment of cancer.
Read More
Pink and orange test tubes
Substance use & poisoning

Addex and Indivior select compounds from GABA-B PAM collaboration

Aug. 27, 2024
Addex Therapeutics Ltd. and Indivior plc have announced the selection of clinical candidates from their γ-aminobutyric acid subtype B (GABA-B) positive allosteric modulator (PAM) research collaboration.
Read More
Cancer

Arcus Biosciences describes discovery, discloses structure of AB-521

Aug. 27, 2024
Arcus Biosciences Inc. recently disclosed the chemical structure of AB-521 (casdatifan), an orally available small-molecule inhibitor of hypoxia-inducible factor 2α (HIF-2α) in early clinical development for the treatment of advanced solid tumors with a high prevalence of molecular alterations associated with pseudohypoxia, such as clear cell renal cell carcinoma (ccRCC).
Read More
Hair follicle containing phagocytic stem cells
Dermatologic

Stem cells eat dead cells to ensure tissue integrity

Aug. 27, 2024
By Mar de Miguel
Phagocytosis – eliminating millions of dead cells every day – requires specialized cells such as macrophages, the true professionals, which migrate to engulf waste and dying cells. But they are not the only ones that can perform this task, as scientists at Howard Hughes Medical Institute (HHMI) discovered when they investigated hair follicle stem cells (HFSCs), a tissue in constant regeneration, to clarify how dying cells are detected and cleared in the epithelium and the mesenchyme.
Read More
Cancer

Zymedi discovers new KARS inhibitors

Aug. 26, 2024
Zymedi Co. Ltd. has patented compounds acting as lysyl tRNA synthetase (KARS) inhibitors and reported to be useful for the treatment of cancer metastasis, inflammation, fibrosis and cardiovascular disorders.
Read More
Neurology/psychiatric

Lucy Therapeutics identifies F1F0 ATPase hydrolase inhibitors

Aug. 26, 2024
Lucy Therapeutics Inc. has disclosed new mitochondrial F1F0 ATPase hydrolase inhibitors potentially useful for the treatment of cancer, acute coronary syndrome, ischemia, neurodegeneration and Parkinson's disease.
Read More
Cancer

DGK-ζ inhibitors disclosed in Beigene patent

Aug. 26, 2024
Beigene Ltd. has identified diacylglycerol kinase ζ (DGK-ζ) inhibitors reported to be useful for the treatment of cancer.
Read More
Neurology/psychiatric

Janssen Pharmaceutica reports new NLRP3 inflammasome inhibitors

Aug. 26, 2024
Several recent Janssen Pharmaceutica NV patents describe new NLRP3 inflammasome inhibitors reported to be useful for the treatment of traumatic brain injury, multiple sclerosis, amyotrophic lateral sclerosis, dementia, Huntington’s, Parkinson’s, Alzheimer’s and motor neuron diseases.
Read More
Neurology/psychiatric

Purdue Research Foundation patents compounds to inhibit protein aggregation

Aug. 26, 2024
Purdue Research Foundation has discovered compounds for inhibiting protein aggregation potentially useful for the treatment of wild-type transthyretin amyloidosis, type 2 diabetes, amyotrophic lateral sclerosis and more.
Read More
Previous 1 2 … 320 321 322 323 324 325 326 327 328 … 17774 17775 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 3, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 3, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for July 1, 2025
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • Robert Paris, vice president, Moderna

    Moderna expands mRNA tech to latent viruses, cancer, rare disease

    BioWorld
    Post pandemic, Moderna Inc. is broadening the applications of mRNA technology to cancer, rare diseases, latent viruses and respiratory viruses, “taking advantage”...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe